ReviewAmerican journal of cancer research2024
RBFOX2 as a regulatory linchpin in cancer: insights from a comprehensive review of its roles in tumorigenesis.
Review in American journal of cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The RNA-binding protein RBFOX2 suppresses colorectal cancer proliferation and metastasis by reducing FUBP1 mRNA stability to induce mitochondrial dysfunction and ferroptosis.Discover oncology · 2026Article
- KnockRBP: an integrated multi-omics database of functional perturbation profiles for RNA-binding proteins.Nucleic acids research · 2026Article
- Dynamics and regulatory role of 5-methylcytosine modification in mRNA colocalized with RNA G-quadruplex structure in mouse development.Mammalian genome : official journal of the International Mammalian Genome Society · 2025Article
- Alternative Splicing and CaV-Associated Channelopathies.Wiley interdisciplinary reviews. RNAReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RNA-binding proteins (RBPs) are essential regulators of RNA expression during both transcriptional and post-transcriptional processes. Recent evidence indicates that dysregulation of RBPs is associated with cancer initiation and progression. Among these, RBFOX2 has been identified as exhibiting variable expression patterns across different cancers and is implicated in various malignant processes, including tumor growth, metastasis, ferroptosis, stemness, and chemoresistance. Despite these findings, the precise mechanisms by which RBFOX2 contributes to carcinogenesis remain largely unexplored. In this comprehensive review, we systematically examine the multifaceted functions of RBFOX2 in tumorigenesis, with a particular focus on its roles in alternative splicing, mRNA stability, and microRNA processing. Upon elucidating the specific roles of RBFOX2 in various cancers, targeted drugs can be devised to inhibit cancer development. Furthermore, we evaluate the specific roles of RBFOX2 in various cancer types, including pancreatic ductal adenocarcinoma, myeloid leukemia, and nasopharyngeal carcinoma. By providing an in-depth analysis, we aim to establish RBFOX2 as a potential diagnostic and therapeutic target in cancer biology and treatment, thereby offering new insights for future research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.